US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

U.S. cancer centers are scrambling to enroll patients in an early access program for a highly promising pancreatic cancer drug from ​Revolution Medicines while they await what they hope will be a speedy FDA approval.